Select Publications

Conference Presentations

Daniels B, 2019, 'Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia’s Pharmaceutical Benefits Scheme (PBS) data', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'Validating administrative health data in Australia', presented at Asian Conference on Pharmacoepidemiology, Kyoto, Japan, 11 October 2019 - 13 October 2019

Daniels B, 2019, 'A Day in the Life: Prescription Medicine Use in Australia', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Philadelphia, PA, USA, 26 August 2019 - 28 August 2019

Daniels B, 2019, 'Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM)', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czechia, 24 August 2019 - 26 August 2019

Daniels B, 2017, 'Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2015', presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 06 December 2017 - 10 December 2017

Daniels B, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B, 2017, 'Patterns of care for long-term surviving trastuzumab-treated patients with HER2-positive metastatic breast cancer (HER2+MBC): an Australian whole-of-population cohort study', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management., 30 October 2017 - 01 November 2017

Daniels B, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Daniels B, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Daniels B, 2016, 'Tracking trastuzumab (H) therapy in early- through late-stage HER2-positive breast cancer (HER2+BC) in Australia: A national, retrospective cohort study', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 26 August 2016 - 29 August 2016

Daniels B, 2016, 'Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early- through late-stage HER2-positive breast cancer (HER2+BC)', presented at International Population Data Linkage Conference, Swansea, Wales, UK, 23 August 2016 - 26 August 2016

Daniels B, 2015, 'Relative misclassification (RM) of new medicine users based on look-back period', presented at Australian Population Health Congress, 07 September 2015 - 09 September 2015

Peng J; Liu JJ; Daniels B; Firriolo J; Laaksonen MA; Hawkins NJ; Meagher AP; Hayes I; Croxford M; Cai S; Ward RL, 2014, 'RETROSPECTIVE COMPARISON OF RECTAL CANCER TREATMENT IN CHINA AND AUSTRALIA FROM 1995-2012', Vol. 10, pp. 106 - 106, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000345350900095&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Daniels B; Ward R; Pearson S-A, 2013, 'DO PHARMACEUTICAL CLAIMS ACCURATELY REFLECT ONCOLOGY PRESCRIBING PRACTICE: EVIDENCE FROM AN AUSTRALIAN HER2+EARLY BREAST CANCER COHORT (HER2EBC)', Vol. 9, pp. 123 - 123, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Srasuebkul P; Ward R, 2013, 'HER2 POSITIVE EARLY BREAST CANCER (HER2EBC): AN AUSTRALIAN PATTERN OF CARE STUDY', Vol. 9, pp. 81 - 81, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B, 2012, 'Building chemotherapy protocols: linking dispensing and administration records from the Elements of Cancer Care study', presented at Australian Population Health Congress, Adelaide, SA, 10 September 2012 - 12 September 2012


Back to profile page